Skip to main content

Lung Preservation with Tocilizumab in Early Systemic Sclerosis

Feb 21, 2021 11:17 pm

Arthritis & Rheumatology has published the results of a subanalysis from tocilizumab (TCZ) clinical trials showing that Il-6 inhibition was associated with preservation of lung function patients with early systemic sclerosis (SSc).

The focuSSced trial included 210 patients with early diffuse SSc, two-thirds (136) of whom had interstitial lung disease. While those on TCZ showed no change in forced vital capacity (FVC), there was a decline in FVC in placebo-treated patients over 48 weeks (least squared mean change -0.1% TCZ vs. ‐6.3% PBO).  The same differences were noted for those with mild, moderate, and severe ILD between groups (TCZ ‐4.1, 0.7, and 2.1; vs  PBO ‐10.0, ‐5.7, and ‐6.7).

Tocilizumab in early SSc with interstitial lung disease stabilized forced vital capacity over 48 weeks and treatment‐related preservation was independent of radiographic fibrosis severity.

The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.